Glaucoma Medications in Eye Care
Glaucoma Medication Management
Glaucoma medications play a critical role in the management of intraocular pressure (IOP), which is a crucial factor in preventing optic nerve damage and preserving vision in conditions such as open-angle glaucoma and angle-closure glaucoma. These medications work through various mechanisms to lower IOP, either by reducing the production of aqueous humor or by increasing its outflow from the eye. The primary classes of glaucoma treatments include beta-blockers, prostaglandin analogs, alpha agonists, carbonic anhydrase inhibitors, and cholinergic agents, each with its own unique mode of action and potential side effects. Additionally, combination medications that contain two different classes of drugs are available to enhance treatment efficacy and improve patient compliance.
Glaucoma Medications
Brand | Generic | Dosing | Amount | Ages | Pregnancy | Mechanism |
---|---|---|---|---|---|---|
brimonidine 0.1/0.15/0.2*% | tid | 5/10/15mL | >2 years | B | α-2 agonist ↓ aqueous production ↑ outflow | |
brinzolamide 1% | tid | 5/10/15mL | NA | C | carbonic anhydrase inhibitor ↓ aqueous production | |
brimonidine 0.2% timolol 0.5% | bid | 5/10/15mL | >2 years | C | α-2 agonist β blocker ↓ aqueous production, ↑ outflow | |
dorzolamide 2% timolol 0.5% | bid | 5/10mL | >2 years | C | carbonic anhydrase inhibitor β blocker ↓ aqueous production | |
acetazolamide | 500mg po bid | 125/250mg 500mg 'Sequels' | >12 years | C | carbonic anhydrase inhibitor ↓ aqueous production | |
pilocarpine 1/2/4% | qd-qid | 15mL | >2 years | C | cholinergic agonist ↑ outflow | |
bimatoprost 0.01/0.03*% | qhs | 2.5/5/7.5mL | >16 years | C | prostaglandin analogue ↑ outflow | |
netarsudil 0.02% | qhs | 2.5mL | NA | NA | Rho kinase inhibitor ↑ outflow | |
netarsudil 0.02% latanoprost 0.005% | qhs | 2.5mL | NA | NA | Rho kinase inhibitor prostaglandin analogue ↑ outflow | |
brimonidine 0.2% brinzolamide 1% | tid | 8mL | >2 years | C | α-2 agonist carbonic anhydrase inhibitor ↓ aqueous production ↑ outflow | |
timolol maleate 0.25/0.5% | bid | 5/10/15mL | >2 years | C | β blocker ↓ aqueous production | |
travoprost 0.004% | qhs | 2.5/5mL | >16 years | C | prostaglandin analogue ↑ outflow | |
dorzolamide 2% | bid-tid | 5/10mL | >2 years | C | carbonic anhydrase inhibitor ↓ aqueous production | |
latanoprostene bunod 0.024% | qhs | 5mL | >16 years | NA | prostaglandin analogue ↑ outflow | |
latanoprost 0.005% | qhs | 2.5mL | NA | C | prostaglandin analogue ↑ outflow | |
latanoprost 0.005% (BAK free) | qhs | 2.5mL | NA | C | prostaglandin analogue ↑ outflow | |
tafluprost 0.0015% | qhs | 30/90 pack | Not Recommended | C | prostaglandin analogue ↑ outflow |